{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"These criteria included measures of alteration in the natural history of disease, hematologic improvement, cytogenetic response, and improvement in health-related quality of life.The IWG criteria define 4 aspects of responses based on treatment goals: (1) altering the natural history of the disease, (2) cytogenetic response, (3) hematologic improvement (HI), and (4)Quality of Life (QOL)","groups":[{"description":"Bendamustine: On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\\^2, and then to 60 mg/m\\^2 bendamustine on days 1 and 4 if ANC is not \\>1 x 10\\^9/L and platelets are not \\>50 x 10\\^9/L on day 1 of each cycle.\n\nPatients will be treated until disease progression after at least one cycle of treatment.\n\nBortezomib: On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\\^2 followed by bendamustine given at 90 mg/m\\^2. Patients will be dose reduced to 75 mg/m\\^2, and then to 60 mg/m\\^2 bendamustine on days 1 and 4 if ANC is not \\>1 x 10\\^9/L and platelets are not \\>50 x 10\\^9/L on day 1 of each cycle.\n\nPatients will be treated until disease progression after at least one cycle of treatment.","id":"OG000","title":"Bortezomib and Bendamustine"}],"populationDescription":"Participant data was not analyzed because PI left institution","reportingStatus":"POSTED","timeFrame":"8 weeks","title":"Percent Change Response Rate (Partial Response or Better After 2 Cycles) Following Treatment With Bortezomib and Bendamustine","type":"PRIMARY"}